Lara JD - Bicara Therapeutics Chief Secretary
| BCAX Stock | 20.79 0.17 0.81% |
Executive
Lara JD is Chief Secretary of Bicara Therapeutics Common
| Age | 52 |
| Address | 116 Huntington Avenue, Boston, MA, United States, 02116 |
| Phone | 617 468 4219 |
| Web | https://www.bicara.com |
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Dr Esq | Enliven Therapeutics | 47 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Charbel PharmD | Inhibrx | N/A | |
| Josep Garcia | Inhibrx | N/A | |
| Jeffrey Jensen | Inhibrx | N/A | |
| Carlos Bais | Inhibrx | N/A | |
| Ashraf Amanullah | Inhibrx | 56 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| David MBA | Inhibrx | N/A | |
| Bonne MBA | Inhibrx | 47 | |
| Brendan Eckelman | Inhibrx | 45 | |
| Zamaneh MD | Tff Pharmaceuticals | 60 | |
| Helen MD | Enliven Therapeutics | 61 | |
Bicara Therapeutics Leadership Team
Elected by the shareholders, the Bicara Therapeutics' board of directors comprises two types of representatives: Bicara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bicara. The board's role is to monitor Bicara Therapeutics' management team and ensure that shareholders' interests are well served. Bicara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bicara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MD MBA, Senior Affairs | ||
| Angela Windt, VP Affairs | ||
| Lara JD, Chief Secretary | ||
| Ryan PharmD, COO President | ||
| Rachel Salazar, SVP Operations | ||
| JeanPaul Rodrique, Senior Assurance | ||
| Sathish Hasige, Senior Chain | ||
| Ivan MBA, Chief Officer | ||
| David MD, Chief Officer | ||
| Claire MBA, CEO Director |
Bicara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bicara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 577.25 M | ||||
| Shares Outstanding | 54.39 M | ||||
| Shares Owned By Insiders | 0.42 % | ||||
| Number Of Shares Shorted | 2.07 M | ||||
| Price To Book | 2.15 X | ||||
| EBITDA | (58.3 M) | ||||
| Total Debt | 382.75 M | ||||
| Book Value Per Share | (5.10) X | ||||
| Earnings Per Share | (3.75) X | ||||
| Market Capitalization | 1.1 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.